# Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Study · id `cardio:ct-nct04790513` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04790513](<https://clinicaltrials.gov/study/NCT04790513>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04790513

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

## Technical summary

Registry record NCT04790513. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 204 participants (enrolled count; ClinicalTrials.gov record NCT04790513, source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)
- Started: 2021-04-22 (actual) (ClinicalTrials.gov record NCT04790513, source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)
- Primary completion: 2022-09-30 (actual) (ClinicalTrials.gov record NCT04790513, source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)
- Completion: 2022-12-31 (actual) (ClinicalTrials.gov record NCT04790513, source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04790513, source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04790513-2023-03-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
- Acronym: LIBerate-H2H
- Condition: Hypercholesterolemia
- Condition: Cardiovascular Diseases
- Intervention (Biological): lerodalcibep
- Intervention (Biological): evolocumab
- Intervention (Biological): alirocumab
- Lead sponsor: LIB Therapeutics LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: LIB Therapeutics LLC (`cardio:org-lib-therapeutics-llc`)

## Provenance

Content hash: 44b7842e5ea34aecbb1125607b406009660bb3892979b7b51539b4bcd0d846e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
